HEAT BIOLOGICS INC (HTBX) Stock Price & Overview

NYSEARCA:HTBXUS42237K4094

Current stock price

2.38
+0.01 (+0.42%)
Last:

The current stock price of HTBX is 2.38 null. Today HTBX is up by 0.42%. In the past month the price decreased by -22.98%. In the past year, price decreased by -61.92%.

HTBX Key Statistics

52-Week Range2.07 - 10.85
Current HTBX stock price positioned within its 52-week range.
1-Month Range2.2201 - 3.38
Current HTBX stock price positioned within its 1-month range.
Market Cap
61.047M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-1.41
Dividend Yield
N/A

HTBX Stock Performance

Today
+0.42%
1 Week
-2.46%
1 Month
-22.98%
3 Months
-13.77%
Longer-term
6 Months -55.51%
1 Year -61.92%
2 Years N/A
3 Years N/A
5 Years N/A
10 Years N/A

HTBX Stock Chart

HEAT BIOLOGICS INC / HTBX Daily stock chart

HTBX Technical Analysis

ChartMill assigns a technical rating of 0 / 10 to HTBX. When comparing the yearly performance of all stocks, HTBX is a bad performer in the overall market: 81.8% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

HTBX Fundamental Analysis

ChartMill assigns a fundamental rating of 4 / 10 to HTBX. HTBX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

HTBX Earnings

Next Earnings DateMay 17, 2022
Last Earnings DateMar 11, 2022
PeriodQ4 / 2021
EPS Reported-$0.54
Revenue Reported
EPS Surprise -65.44%
Revenue Surprise 36.61%

HTBX Forecast & Estimates

10 analysts have analysed HTBX and the average price target is 11.6 null. This implies a price increase of 387.5% is expected in the next year compared to the current price of 2.38.

For the next year, analysts expect an EPS growth of -23.7% and a revenue growth 128.57% for HTBX


Analysts
Analysts82
Price Target11.6 (387.39%)
EPS Next Y-23.7%
Revenue Next Year128.57%

HTBX Groups

Sector & Classification

Sub-Industry
Biotechnology
Index Membership

HTBX Financial Highlights

Over the last trailing twelve months HTBX reported a non-GAAP Earnings per Share(EPS) of -1.41. The EPS increased by 9.62% compared to the year before.


Income Statements
Revenue(TTM)2.11M
Net Income(TTM)-35.07M
Industry RankSector Rank
PM (TTM) -1658.78%
ROA -28.99%
ROE N/A
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-2600%
Sales Q2Q%2.18%
EPS 1Y (TTM)9.62%
Revenue 1Y (TTM)-28.09%

HTBX Ownership

Ownership
Inst Owners1.57%
Shares25.65M
Float24.32M
Ins Owners5.77%
Short Float %N/A
Short RatioN/A

About HTBX

Company Profile

HTBX logo image Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company is headquartered in Morrisville, North Carolina and currently employs 49 full-time employees. The company went IPO on 2013-07-24. The Company’s gp96 platform is designed to activate the immune system. This platform has applications in cancer and infectious disease. Its platform leverages gp96’s role as a natural molecular warning system that presents antigens to the immune system. The firm also develops ANTHIM, a treatment for inhalation anthrax. ANTHIM is used in the United States and Canada and sold under the brand name Obiltoxaximab SFL in Europe and the United Kingdom. ANTHIM is a monoclonal antibody that binds to the protective antigen (PA) component of anthrax toxin. ANTHIM’s toxin neutralizing activity prevents entry of anthrax toxin into susceptible cells, avoiding further spread of the toxin throughout the body and the ensuing tissue damage. ANTHIM is supplied as single-dose vials for Intravenous Therapy (IV) infusion. ANTHIM is indicated in adult and pediatric patients.

Company Info

IPO: 2013-07-24

HEAT BIOLOGICS INC

627 Davis Drive, Suite 400

Morrisville NORTH CAROLINA 27560 US

CEO: Jeffrey Wolf

Employees: 49

HTBX Company Website

Phone: 19192407133.0

HEAT BIOLOGICS INC / HTBX FAQ

What does HEAT BIOLOGICS INC do?

Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company is headquartered in Morrisville, North Carolina and currently employs 49 full-time employees. The company went IPO on 2013-07-24. The Company’s gp96 platform is designed to activate the immune system. This platform has applications in cancer and infectious disease. Its platform leverages gp96’s role as a natural molecular warning system that presents antigens to the immune system. The firm also develops ANTHIM, a treatment for inhalation anthrax. ANTHIM is used in the United States and Canada and sold under the brand name Obiltoxaximab SFL in Europe and the United Kingdom. ANTHIM is a monoclonal antibody that binds to the protective antigen (PA) component of anthrax toxin. ANTHIM’s toxin neutralizing activity prevents entry of anthrax toxin into susceptible cells, avoiding further spread of the toxin throughout the body and the ensuing tissue damage. ANTHIM is supplied as single-dose vials for Intravenous Therapy (IV) infusion. ANTHIM is indicated in adult and pediatric patients.


What is the current price of HTBX stock?

The current stock price of HTBX is 2.38 null. The price increased by 0.42% in the last trading session.


Does HTBX stock pay dividends?

HTBX does not pay a dividend.


How is the ChartMill rating for HEAT BIOLOGICS INC?

HTBX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 4 out of 10.


Can you provide the upcoming earnings date for HEAT BIOLOGICS INC?

HEAT BIOLOGICS INC (HTBX) will report earnings on 2022-05-17, before the market open.


Who owns HEAT BIOLOGICS INC?

You can find the ownership structure of HEAT BIOLOGICS INC (HTBX) on the Ownership tab.